Aethlon Medical Inc. (AEMD) - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of a Special Meeting of Stockholders held by Aethlon Medical, Inc. on May 13, 2025. The meeting was conducted virtually to address critical corporate governance and capital structure proposals.
Key Financial Metrics
The filing does not provide specific financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the voting outcomes of the Special Meeting.
Material Changes and Voting Results
As of the record date (March 27, 2025), there were 16,061,096 shares of common stock outstanding. Approximately 38.78% of shares were represented at the meeting, establishing a quorum. All three proposals presented were approved by stockholders:
- Proposal 1 (Reverse Stock Split): Approved a reverse stock split of common stock at a ratio between 1-for-5 and 1-for-12. The Board of Directors retains discretion to determine the exact ratio and effective date, provided it occurs no later than May 13, 2026.
- Proposal 2 (Inducement Warrants): Approved the issuance of common stock upon exercise of Inducement Warrants issued in a private placement and the Reset of Exercise Price provision contained therein.
- Proposal 3 (Adjournment): Approved the authority to adjourn the meeting to solicit additional proxies if necessary. However, the chair did not exercise this option as all other proposals passed.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors beyond the standard incorporation by reference of the Definitive Proxy Statement filed on April 18, 2025.
Investor Verification Checklist
- Verify the specific reverse stock split ratio and effective date once determined by the Board of Directors.
- Review the Definitive Proxy Statement (Schedule 14A) filed on April 18, 2025, for detailed terms regarding the Inducement Warrants and the Reset of Exercise Price provision.
- Monitor subsequent filings for the official implementation of the reverse stock split and any resulting changes to share count and trading price.